tetano
Editor, Senior Moderator
Med Res Rev
. 2021 Jan 3.
doi: 10.1002/med.21776. Online ahead of print.
Therapeutic targets and potential agents for the treatment of COVID-19
Yinuo Wu[SUP] 1 [/SUP], Zhe Li[SUP] 1 [/SUP], Yun-Song Zhao[SUP] 1 [/SUP], Yi-You Huang[SUP] 1 [/SUP], Mei-Yan Jiang[SUP] 1 [/SUP], Hai-Bin Luo[SUP] 1 2 [/SUP]
Affiliations
Abstract
The outbreak of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has become a global crisis. As of November 9, COVID-19 has already spread to more than 190 countries with 50,000,000 infections and 1,250,000 deaths. Effective therapeutics and drugs are in high demand. The structure of SARS-CoV-2 is highly conserved with those of SARS-CoV and Middle East respiratory syndrome-CoV. Enzymes, including RdRp, M[SUP]pro[/SUP] /3CL[SUP]pro[/SUP] , and PL[SUP]pro[/SUP] , which play important roles in viral transcription and replication, have been regarded as key targets for therapies against coronaviruses, including SARS-CoV-2. The identification of readily available drugs for repositioning in COVID-19 therapy is a relatively rapid approach for clinical treatment, and a series of approved or candidate drugs have been proven to be efficient against COVID-19 in preclinical or clinical studies. This review summarizes recent progress in the development of drugs against SARS-CoV-2 and the targets involved.
Keywords: COVID-19; Mpro; PLpro; RdRp; SARS-CoV-2; dipyridamole; drug targets; potential agents; remdesivir.
. 2021 Jan 3.
doi: 10.1002/med.21776. Online ahead of print.
Therapeutic targets and potential agents for the treatment of COVID-19
Yinuo Wu[SUP] 1 [/SUP], Zhe Li[SUP] 1 [/SUP], Yun-Song Zhao[SUP] 1 [/SUP], Yi-You Huang[SUP] 1 [/SUP], Mei-Yan Jiang[SUP] 1 [/SUP], Hai-Bin Luo[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33393116
- DOI: 10.1002/med.21776
Abstract
The outbreak of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has become a global crisis. As of November 9, COVID-19 has already spread to more than 190 countries with 50,000,000 infections and 1,250,000 deaths. Effective therapeutics and drugs are in high demand. The structure of SARS-CoV-2 is highly conserved with those of SARS-CoV and Middle East respiratory syndrome-CoV. Enzymes, including RdRp, M[SUP]pro[/SUP] /3CL[SUP]pro[/SUP] , and PL[SUP]pro[/SUP] , which play important roles in viral transcription and replication, have been regarded as key targets for therapies against coronaviruses, including SARS-CoV-2. The identification of readily available drugs for repositioning in COVID-19 therapy is a relatively rapid approach for clinical treatment, and a series of approved or candidate drugs have been proven to be efficient against COVID-19 in preclinical or clinical studies. This review summarizes recent progress in the development of drugs against SARS-CoV-2 and the targets involved.
Keywords: COVID-19; Mpro; PLpro; RdRp; SARS-CoV-2; dipyridamole; drug targets; potential agents; remdesivir.